Search Results for “Alzheimer's” – Page 6 – media

Alzheimer’s Blood Test Could Soon Replace Invasive Spinal Taps and Brain Scans

Historically, Alzheimer’s disease was primarily diagnosed based on observable symptoms, particularly when individuals started exhibiting memory and cognitive difficulties. However, it’s been revealed through research that up to a third of individuals diagnosed with Alzheimer’s based solely on cognitive symptoms have been incorrectly diagnosed, with their symptoms stemming from other causes. The accurate identification of Alzheimer’s disease has become increasingly crucial, especially since the introduction of the first treatments that can slow the disease’s progression, along with other promising drugs currently in development. These treatments are potentially more effective when administered early, highlighting the need for early detection of the disease. Therefore, to qualify for Alzheimer’s therapies, patients must show cognitive impairment and test positive for amyloid plaques, which are distinctive to Alzheimer’s. Techniques like amyloid positron emission tomography (PET) brain scans, cerebrospinal fluid analyses, and blood tests are used to detect brain amyloid plaques. However, these are only employed ...
- Source: drugdu
- 167
- February 28, 2024
Ultra-Sensitive Blood Test Reflects Brain Damage and Predicts Functional Outcomes after Ischemic Stroke

Acute ischemic stroke, which is the most common type of stroke, occurs due to a lack of oxygen in the brain caused by a blood clot. Currently, there are no blood-based biomarkers that can accurately reflect the acute neuronal damage following a stroke or predict the clinical outcomes for stroke patients. Now, a new study has demonstrated that an ultra-sensitive blood test can reflect brain damage and also predict functional outcomes after acute ischemic stroke. Brain-derived tau (BD-tau), a protein indicative of neuronal breakdown in the central nervous system, particularly in Alzheimer’s disease, has been the focus of recent research. Last year, a team from the University of Gothenburg (Gothenburg, Sweden) developed a novel blood test to measure BD-tau levels. This breakthrough represents a significant step towards creating a tool for tracking and monitoring Alzheimer’s disease progression. In their latest research, this team explored whether BD-tau could also serve as ...
- Source: drugdu
- 164
- February 23, 2024
Biogen abandons Aduhelm efforts, focuses on Eisai-partnered Leqembi and pipeline drugs

More than two years after Aduhelm’s controversial and ill-fated FDA accelerated approval, Biogen is discontinuing the Alzheimer’s disease therapy after walking a rocky path. Wednesday, Biogen said it’s pulling all efforts from the first-of-its-kind anti-amyloid beta therapy to focus on Leqembi, its Eisai-partnered newer medicine, and its pipeline candidates. The newer drug, Leqembi, won a full FDA approval early last year, making the partners’ marketing efforts on the therapy much simpler than was the case with Aduhelm. Biogen is taking a $60 million charge and is discontinuing all development and sales of Aduhelm, the company said. It’s terminating the ENVISION clinical study, which sought to confirm the benefit of the medicine as required under its 2021 accelerated approval. The decision follows Biogen’s move to launch a strategic review in early 2023 under new CEO Chris Viehbacher, the former Sanofi chief who joined the Massachusetts drugmaker in November 2022. During that ...
- Source: drugdu
- 203
- February 2, 2024
Pfizer PARP inhibitor Talzenna nabs EU combo nod

• Pfizer’s PARP inhibitor Talzenna has gained European approval when used in combination with Pfizer and Astellas’ Xtandi to treat adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. This approval makes Talzenna the first PARP inhibitor in Europe to be licensed in combination with Xtandi in mCRPC, Pfizer said in a release. The European Commission approved Pfizer’s application based on data from the phase 3 TALAPRO-2 trial, which showed that the combo cut the risk of disease progression or death in patients with mCRPC compared with placebo and Xtandi. Last June, the FDA approved the combination to treat adults with HRR gene-mutated mCRPC. • In another regulatory win for Pfizer, the FDA is reviewing the company’s full approval application on Genmab-partnered Tivdak. Under its priority review timeline, the FDA is assessing whether to convert Tivdak’s accelerated approval into a full nod to treat ...
- Source: drugdu
- 124
- January 11, 2024
GLP-1 agonists can blunt obesity-associated health problems

Science has named the development of glucagon like peptide-1 (GLP-1) agonists and this year’s discovery that these drugs can blunt obesity-associated health problems as its 2023 Breakthrough of The Year. Although obesity’s causes span genetic, physiological, environmental, and social factors, as a medical problem, obesity’s risks can be life-threatening – including heart disease, diabetes, arthritis, liver disease, and certain cancers. Drug treatments for obesity have had “a sorry past, one often intertwined with social pressure to lose weight and the widespread belief that excess weight reflects weak willpower,” writes Jennifer Couzin-Frankel in the Breakthrough news feature. However, a new class of drug therapies for weight loss has emerged and is showing promising results. Originally developed to treat diabetes nearly 20 years ago, the excitement surrounding GLP-1 drugs to treat obesity has recently exploded. And this year, two landmark clinical trials that showed in large numbers that GLP-1 agonists produced meaningful ...
- Source: drugdu
- 121
- December 18, 2023
Discovery of Rogue Protein Paves Way for Diagnostic Test to Detect Early-Onset Dementia

Neurodegenerative disorders are often marked by the buildup of amyloid filament inclusions of specific proteins in the brain. These proteins are critical in diagnosing and treating the associated diseases. Frontotemporal lobar degeneration (FTLD) is one such disorder, leading to frontotemporal dementia, which ranks just behind Alzheimer’s disease in prevalence. In about 10% of FTLD cases, the identity of the filament-forming protein was previously unknown. The protein FUS was the suspected culprit, given its presence in brain inclusions and its known genetic role in some instances of amyotrophic lateral sclerosis, another neurodegenerative condition. Now, researchers using electron cryo-microscopy have unexpectedly found that the filaments are instead formed by the protein TAF15. The research team from MRC Laboratory of Molecular Biology (Cambridge, UK) extracted amyloid filaments from the brains of four individuals affected by this type of FTLD. They carried out neuropathological examinations on the brain tissues obtained. Employing electron cryo-microscopy, they ...
- Source: drugdu
- 92
- December 12, 2023
Biogen’s Aduhelm headache returns as appeals court revives part of investor lawsuit

For more than a year, Biogen has been working to turn the page from its Aduhelm fiasco and focus on its newer Eisai-partnered Alzheimer’s disease medicine Leqembi. But a new ruling from the U.S. Court of Appeals for the First Circuit will make that effort a little tougher. After Biogen last year won the dismissal of an investor lawsuit surrounding disclosures into its Aduhelm research, the appeals court has reversed the ruling—in part—by focusing on one statement made by Biogen’s former chief medical officer Al Sandrock. Specifically, the appeals court flagged Sandrock’s statement from the company’s second-quarter earnings call in 2020. During the call, Sandrock stated that “[Y]ou really need to get to the higher dose,” adding, “I think our data are all consistent with that.” The court dubbed this the “all data” statement and painstakingly broke down the context behind the remark. To refresh readers’ memory, Biogen in March ...
- Source: drugdu
- 134
- October 14, 2023
Specific navigational errors may indicate early signs of Alzheimer’s disease

People with early Alzheimer’s disease have difficulty turning when walking, according to a new study using virtual reality led by UCL researchers. The study, published in Current Biology, used a computational model to further explore the intricacies of navigational errors previously observed in Alzheimer’s disease. Researchers, led by Professor Neil Burgess and colleagues in the Space and Memory group* at the UCL Institute of Cognitive Neuroscience, grouped participants into three categories: healthy younger participants (31 total), healthy elderly participants (36 total) and patients with mild cognitive impairment (43 total). They then asked them to complete a task while wearing virtual reality goggles, which allowed them to make real movements. In the trial, participants walked an outbound route guided by numbered cones, consisting of two straight legs connected by a turn. They then had to return to their starting position unguided. The task was performed under three different environmental conditions aimed ...
- Source: drugdu
- 120
- October 13, 2023
Researchers discover how neurons die in Alzheimer’s disease

Scientists from the UK’s Dementia Research Institute at University College London (UCL) and VIB-KU Leuven have discovered the cause of the death of neurons in Alzheimer’s disease (AD), opening up potential avenues to develop new treatments for the condition. The researchers found that a programmed form of cell death, known as necroptosis, is initiated when neurons are exposed to amyloid plaques and tau tangles. The researchers created a new model to replicate and connect AD hallmark features – amyloid plaques, tau tangles, and death of neurons – by implanting both healthy human and mouse neurons into the brains of AD mouse models. They discovered that only human neurons displayed Alzheimer’s features, including tau tangles and neuronal cell loss. These findings suggest that humans have specific factors that play in Alzheimer’s that standard mouse models cannot replicate, as their neurons are more resilient to amyloid pathology. Upon further research, the team ...
- Source: drugdu
- 107
- September 22, 2023
Gut problems may be early sign of Parkinson’s disease

By Michelle Roberts Digital health editor Gut problems including constipation, difficulty swallowing and an irritable bowel may be an early warning sign of Parkinson’s disease in some people, a new study suggests. The findings in the journal Gut add more evidence to the idea that brain and bowel health are intimately linked. Understanding why gut issues happen might allow earlier treatment of Parkinson’s, say the researchers. Parkinson’s is progressive, meaning the brain disorder gets worse over time. What is Parkinson’s? People with Parkinson’s do not have enough of the chemical dopamine in their brain because some of the nerve cells that make it are damaged. This causes symptoms including involuntary tremor or shaking, slow, shuffling movements and stiff muscles. Although there is currently no cure, treatments are available to help reduce the main symptoms and maintain quality of life for as long as possible. Spotting the disease even sooner – ...
- Source: drugdu
- 103
- August 28, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.